The global metastatic melanoma drug market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of metastatic melanoma and the introduction of new drugs in the market. The global metastatic melanoma drug market by type includes AG134, AL801, AL803, and AM232.AG134 is a monoclonal antibody that targets CD133+ cells in patients with advanced stage III or IV malignant neoplasms such as breast cancer and prostate cancer. It has been approved for use in Japan since 2016 and it is expected to be approved for use in Europe by 2020. AL801 is an immunotherapy that targets PD-L1 on tumor cells which are found on some types of cancers such as lung cancer, bladder cancer, head & neck squamous cell carcinomas (HNSCC), cervical cancer, ovarian cancer and colorectal cancers among others. It has been approved for use in Japan since 2017 and it will be available for sale globally by 2020-2021 under license from AstraZeneca plc (AZ). It has been approved for use in Japan since 2017 under license from AstraZeneca plc (AZ) but it will not be available until 2020-2021 due to patent issues with AZ's partner company MedImmune LLC who owns patents related to this product outside Asia Pacific region including North America & Europe regions where AZ does not have any rights over this product due to licensing agreement between them both companies signed back in 2007 when they first started working together on developing this product before they split up their partnership back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other.
Some Of The Growth Factors Of This Market:
- Increasing incidence of skin cancer, rising awareness about the disease, and increasing number of patients with metastatic melanoma are some factors that are driving the growth of the global Metastatic Melanoma Drug market.
- The high cost associated with treatment is a major factor restraining the growth of this market.
- Increasing research and development activities in this field will provide opportunities for new players in this market.
- Increasing government funding for research and development activities will also provide opportunities for new players in this market.
Industry Growth Insights published a new data on “Metastatic Melanoma Drug Market”. The research report is titled “Metastatic Melanoma Drug Market research by Types (AGI-134, ALT-801, ALT-803, AMG-232, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Melanoma Drug Market Research Report
By Type
AGI-134, ALT-801, ALT-803, AMG-232, Others
By Application
Hospital, Clinic, Others
By Companies
Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Melanoma Drug Market Report Segments:
The global Metastatic Melanoma Drug market is segmented on the basis of:
Types
AGI-134, ALT-801, ALT-803, AMG-232, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co., Inc.
- Merck KGaA
- Millennium Pharmaceuticals, Inc.
- Morphotek, Inc.
- NewLink Genetics Corporation
- Novartis AG
- Omeros Corporation
- Oncolytics Biotech Inc.
- OncoSec Medical Inc.
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Pharmis Biofarmaceutica, Lda.
- Philogen S.p.A.
- Plexxikon Inc.
Highlights of The Metastatic Melanoma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AGI-134
- ALT-801
- ALT-803
- AMG-232
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Melanoma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic melanoma drug is a medication that is used to treat metastatic melanoma, a type of cancer that has spread from the original tumor to other parts of the body. Metastatic melanoma drugs can help slow or stop the growth of new tumors and may improve the patient's overall health.
Some of the major players in the metastatic melanoma drug market are Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc..
The metastatic melanoma drug market is expected to grow at a compound annual growth rate of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Metastatic Melanoma Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Metastatic Melanoma Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Metastatic Melanoma Drug Market - Supply Chain
4.5. Global Metastatic Melanoma Drug Market Forecast
4.5.1. Metastatic Melanoma Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Metastatic Melanoma Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Metastatic Melanoma Drug Market Absolute $ Opportunity
5. Global Metastatic Melanoma Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Type
5.3.1. AGI-134
5.3.2. ALT-801
5.3.3. ALT-803
5.3.4. AMG-232
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Metastatic Melanoma Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Metastatic Melanoma Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Metastatic Melanoma Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Metastatic Melanoma Drug Demand Share Forecast, 2019-2026
9. North America Metastatic Melanoma Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Type
9.7.1. AGI-134
9.7.2. ALT-801
9.7.3. ALT-803
9.7.4. AMG-232
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Metastatic Melanoma Drug Demand Share Forecast, 2019-2026
10. Latin America Metastatic Melanoma Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Type
10.7.1. AGI-134
10.7.2. ALT-801
10.7.3. ALT-803
10.7.4. AMG-232
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Metastatic Melanoma Drug Demand Share Forecast, 2019-2026
11. Europe Metastatic Melanoma Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Type
11.7.1. AGI-134
11.7.2. ALT-801
11.7.3. ALT-803
11.7.4. AMG-232
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Metastatic Melanoma Drug Demand Share, 2019-2026
12. Asia Pacific Metastatic Melanoma Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Type
12.7.1. AGI-134
12.7.2. ALT-801
12.7.3. ALT-803
12.7.4. AMG-232
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Metastatic Melanoma Drug Demand Share, 2019-2026
13. Middle East & Africa Metastatic Melanoma Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Type
13.7.1. AGI-134
13.7.2. ALT-801
13.7.3. ALT-803
13.7.4. AMG-232
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Metastatic Melanoma Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Metastatic Melanoma Drug Market: Market Share Analysis
14.2. Metastatic Melanoma Drug Distributors and Customers
14.3. Metastatic Melanoma Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co., Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck KGaA
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Millennium Pharmaceuticals, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Morphotek, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. NewLink Genetics Corporation
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis AG
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Omeros Corporation
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Oncolytics Biotech Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. OncoSec Medical Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Ono Pharmaceutical Co., Ltd.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pharmis Biofarmaceutica, Lda.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Philogen S.p.A.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Plexxikon Inc.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook